We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Liquid Biopsy Biomarkers for Aggressive Prostate Cancer Discovered

By LabMedica International staff writers
Posted on 05 Jul 2016
Using targeted proteomics on noninvasive liquid biopsies, researchers have discovered biomarkers that provide signatures of aggressive (extracapsular) prostate cancer (PC), which could enable diagnosis before treatment and so help many low-risk PC patients avoid surgery.

Currently, needle biopsies are used to help diagnose PC, but this technique may not detect hidden tumors or cancer that has already spread beyond the organ. More...
The new research advances the quest to develop a precise, noninvasive diagnostic tool that can address over-treatment of slow-growing, low-risk PC.

"We believe we have found a better way that allows us to predict which patients have a slow-growing versus aggressive PC using non-invasive biomarkers. This could eventually help us personalize cancer treatment for these patients," said principal investigator Prof. Dr. Thomas Kislinger, of Princess Margaret Cancer Centre, University Health Network (UHN; Toronto, Canada), and of University of Toronto.

"A fluid-based biomarker would be ideal … to spare patients with indolent (slow-growing) disease from unnecessary procedures, while identifying and treating those who would benefit from treatment intensification," said co-lead author Dr. Yunee Kim.

The Kislinger team – in collaboration with Paul Boutros, Ontario Institute for Cancer Research (Canada), and O. John Semmes, Eastern Virginia Medical School (Norfolk, VA, USA) – used urine samples containing prostatic secretions from 210 patients after they had undergone digital rectal examinations (DRE, the standard clinical "first step" to determine need for further diagnostic testing of the prostate). The research took four years and involved samples from almost 300 patients.

"We used targeted proteomics to accurately quantify hundreds of proteins in urine samples (post-DRE) to identify liquid biopsy signatures. The first round of research involved 80 patients and quantified 150 proteins that were then narrowed down to 34 for further investigation. The next round involved a second, independent cohort of 210 patients,” said Dr. Kislinger, "Applying computational biology, we used the quantitative data from mass spectrometry to develop the fluid biomarkers for aggressive PC." He added, "The next step will be further studies with urine samples from 1,000 international patients to validate if the biomarkers identified have broader clinical utilities in PC."

The study, by Kim Y, Jeon J, et al, was published online ahead of print June 28, 2016, in the journal Nature Communications.

Related Links:
University Health Network



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Portable Electronic Pipette
Mini 96
New
Gold Member
Hybrid Pipette
SWITCH
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: A schematic illustrating the coagulation cascade in vitro (Photo courtesy of Harris, N., 2024)

ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners

Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read more

Microbiology

view channel
Image: EBP and EBP plus have received FDA 510(k) clearance and CE-IVDR Certification for use on the BD COR system (Photo courtesy of BD)

High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample

Gastrointestinal (GI) infections are among the most common causes of illness worldwide, leading to over 1.7 million deaths annually and placing a heavy burden on healthcare systems. Conventional diagnostic... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.